Business Context and Reporting Period
This Form 6-K filing by DBV Technologies S.A. covers the month of June 2018, specifically dated June 5, 2018. DBV Technologies is a clinical-stage biopharmaceutical company headquartered in Montrouge, France, with additional offices in New York, NY. The company develops Viaskin, a proprietary epicutaneous immunotherapy (EPIT) platform designed to treat food allergies and other immune diseases. Its primary product candidates include Viaskin Peanut, Viaskin Milk, and Viaskin Egg.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a notification of upcoming investor conference participation and does not contain financial statements or quantitative financial data.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing. The document serves solely to announce management's schedule for investor relations activities.
Guidance, Outlook, and Management Commentary
- Investor Conferences: Management will present at two major events in June 2018:
- Susanna Mesa, Chief Business Officer, will present at the Goldman Sachs 39th Annual Global Healthcare Conference on June 13, 2018, in Rancho Palos Verdes, CA.
- Susanna Mesa will participate in a panel discussion at the JMP Securities Life Sciences Conference on June 20, 2018, in New York, NY.
- Webcast Availability: A live webcast of the Goldman Sachs presentation and a replay will be available on the company's Investor Relations website.
- Development Pipeline: The company continues ongoing clinical trials for Viaskin Peanut and Viaskin Milk, preclinical development for Viaskin Egg, and a human proof-of-concept study for Viaskin Milk to treat Eosinophilic Esophagitis.
Key Facts for Investor Verification
- Verify the dates and times of the upcoming presentations at the Goldman Sachs and JMP Securities conferences.
- Confirm the availability of the live webcast and replay on the DBV Technologies investor relations website.
- Review the company's latest Form 20-F or quarterly reports for actual financial performance data, as this filing contains none.
- Monitor the status of clinical trials for Viaskin Peanut and Viaskin Milk, as these are the primary drivers of future value.